Interpace Dx Acquires Cancer Genetics Biopharma Services

In a conference call with investors and analysts Tuesday morning, Interpace CEO Jack Stover noted that the acquisition will both improve the firm’s diagnostic business and expand its commercial offerings.

“If you look at our biomarker capabilities, our products, and our current commercial capabilities in that space, [the acquisition] fits very well in terms of what I’d call the future expansion in biopharma,” Stover said.

According to Interpace, the biopharma business will continue to provide the full suite of molecular and biomarker-based tests for oncology and immuno-oncology drug development customers out of Cancer Genetics’ existing laboratories in Rutherford, New Jersey and Research Triangle Park, North Carolina.

Source: https://www.genomeweb.com/cancer/interpace-dx-acquires-cancer-genetics-biopharma-services